Why the study?
Prompt recognition of acute coronary syndrome remains challenging, prompting an evaluation of the diagnostic and prognostic performance of novel biomarkers for NSTEMI.
Does a novel biomarker panel improve diagnostic accuracy and prognostic evaluation for NSTEMI compared to ESC 0/1 h and 0/3 h algorithms in patients with suspected ACS?
Population
1765 patients with suspected ACS presenting to an Emergency Department
Comparison
Novel biomarker panel vs ESC 0/1 h and 0/3 h algorithms
Design
Single-center observational cohort study
Follow-up
1 year
Authors
Loading...
ESC algorithms retain priority for NSTEMI rule-out; cMyBP-C supports adjunct evaluation in prospective cohorts.
Does a novel biomarker panel improve diagnostic accuracy and prognostic evaluation for NSTEMI compared to ESC 0/1 h and 0/3 h algorithms in patients with suspected ACS?
The ESC 0/1 h and 0/3 h algorithms remain the most effective diagnostic strategies for NSTEMI, though cMyBP-C shows comparable diagnostic accuracy to hs-cTnT and may serve as a useful adjunct.
Yıldırım et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: